Metabolic syndrome and risk of cancer: A systematic review and meta-analysis

Diabetes Care

Volumn 35, Issue 11, 2012, Pages 2402-2411

  Esposito, Katherine ^a   Chiodini, Paolo ^a   Colao, Annamaria ^b   Lenzi, Andrea ^c   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CANCER; BODY MASS; BREAST CANCER; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CLINICAL ASSESSMENT; COLORECTAL CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ETHNIC GROUP; GALLBLADDER CANCER; HUMAN; LIVER CANCER; METABOLIC SYNDROME X; PANCREAS CANCER; POSTMENOPAUSE; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW;

FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; NEOPLASMS; RISK FACTORS; SEX FACTORS;

EID: 84868110731     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0336     Document Type: Article

References (55)

1. Alberti KGMM, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645
2. Zhou JR, Blackburn GL, Walker WA. Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr 2007;86:s817-s819
3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578 (Pubitemid 351232031)
4. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010;47:87-95
5. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010;55:2846-2854
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-W94
7. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558 (Pubitemid 34746062)
8. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F; Risk Factors and Life Expectancy Research Group. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001;10:937-941 (Pubitemid 32844900)
9. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002;11:385-391 (Pubitemid 34408218)
10. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006;107:28-36 (Pubitemid 43941640)
11. Bowers K, Albanes D, Limburg P, et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 2006;164:652-664 (Pubitemid 44453494)
12. Stürmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev 2006;15:2391-2397 (Pubitemid 46048295)
13. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer 2008;44:293-297
14. Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 2008;32:304-314 (Pubitemid 351271779)
15. Inoue M, Noda M, Kurahashi N, et al.; Japan Public Health Center-based Prospective Study Group. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009;18:240-247
16. Matthews CE, Sui X, LaMonte MJ, Adams SA, Hébert JR, Blair SN. Metabolic syndrome and risk of death from cancers of the digestive system. Metabolism 2010;59:1231-1239
17. Stocks T, Lukanova A, Bjørge T, et al.; for the Metabolic Syndrome Cancer Project (Me-Can) Group. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 2010;117:2398-2407
18. Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol 2012;36:141-147
19. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila) 2011;4:1873-1883
20. Shen Z, Wang S, Ye Y, et al. Clinical study on the correlation between metabolic syndrome and colorectal carcinoma. ANZ J Surg 2010;80:331-336
21. Pelucchi C, Negri E, Talamini R, et al. Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 2010;46:1866-1872
22. Kabat GC, Kim M, Chlebowski RT, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2046-2053
23. Bjørge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010;19:1737-1745
24. Agnoli C, Berrino F, Abagnato CA, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010;20:41-48
25. Capasso I, Esposito E, Pentimalli F, et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther 2011;10:1240-1243
26. Porto LAM, Lora KJB, Soares JCM, Costa LOBF. Metabolic syndrome is an independent risk factor for breast cancer. Arch Gynecol Obstet 2011;284:1271-1276
27. Rosato V, Bosetti C, Talamini R, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011;22:2687-2692
28. Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012;131:193-200
29. Shebl FM, Andreotti G, Meyer TE, et al. Metabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China. Br J Cancer 2011;105:1424-1429
30. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011;54:463-471
31. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646-1650 (Pubitemid 39331887)
32. Lund Håheim L, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort ofmiddle-aged Norwegianmen followed for 27 years. Am J Epidemiol 2006;164:769-774 (Pubitemid 44522081)
33. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006;164:1094-1102 (Pubitemid 44851745)
34. Tuohimaa P, Tenkanen L, Syvälä H, et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:302-307 (Pubitemid 46383350)
35. Jaggers JR, Sui X, Hooker SP, et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009;45:1831-1838
36. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009;20:1181-1192
37. Wallner LP, Morgenstern H, McGree ME, et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int 2011;107:929-935
38. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010;19:2088-2096
39. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009;74:185-190
40. Pelucchi C, Serraino D, Negri E, et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011;21:835-841
41. De Nunzio C, Freedland SJ, Miano R, et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011;71:1492-1498
42. Cust AE, Kaaks R, Friedenreich C, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007;14:755-767 (Pubitemid 350074064)
43. Bjørge T, Stocks T, Lukanova A, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010;171:892-902
44. Rosato V, Zucchetto A, Bosetti C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011;22:884-889
45. Friedenreich CM, Biel RK, Lau DCW, et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2384-2395
46. Johansen D, Stocks T, Jonsson H, et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev 2010;19:2307-2317
47. Rosato V, Tavani A, Bosetti C, et al. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Metabolism 2011;60:1372-1378
48. Häggström C, Stocks T, Rapp K, et al. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer 2011;128:1890-1898
49. Almquist M, Johansen D, Björge T, et al. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes Control 2011;22:743-751
50. Bjørge T, Lukanova A, Tretli S, et al. Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project. Int J Epidemiol 2011;40:1667-1677
51. Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an in flammatory issue. Ann N Y Acad Sci 2011;1229:45-52
52. Kaklamani VG, Wisinski KB, Sadim M, et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008;300:1523-1531
53. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17:328-336 (Pubitemid 44397568)
54. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-1685
55. Giugliano D, Ceriello A, Esposito K. Are there specific treatments for the metabolic syndrome? Am J Clin Nutr 2008;87:8-11